Detroit, Dec 18th, 2018, (PENNYSTOCKS.NEWS). Nemaura Medical, Inc. (or the Company) (NASDAQ: $NMRD). The company is developing the sugarBEAT as an affordable, flexible and non-invasive Contiguous Glucose Monitor (CGM). For use by people that are pre-diabetic and those who already have diabetes. The announcement came last week, which proclaimed that the Advanced Technologies and Treatments for Diabetes (ATTD) Conference had received sugarBEAT and the Clinical Performance Data Abstract for the presentation of a poster at Berlin in February 2019.
The company will publish the complete data set, for its newest sugarBEAT clinical programmes which are presented for CE approval. The CE marking is a certification mark that indicates conformity with health in Europe. This includes approximately 12,000 cases of paired data, prompted by 100 patients with about 500 days focused on each patient. The company published their clinical data on their website.
Our team of experts has spent over 300 hours analyzing online brokers. Click HERE to compare online brokers!
Now the SugarBEAT is facing annual stages of CE review, upon the approval of that it’ll launch in the United Kingdom initially, CGM is estimated at 1.38B dollars per annum, this is an addressable market.
A central forum ATTD for clinicians to discuss and present the use of advanced technologies. With their aim of upgrading the protection of people with diabetes at the fastest possible rate. It has become compatible with the high ranked caliber scientific programs. The company has also finished clinical studies recently. That is required for sugarBEAT FDA De Novo submission. In the coming weeks, the company precedes publishing the data on its website, and it is also submitting in March 2019 for FDA approval.
The recent global CGM usage is growing rapidly. The U.S. has the biggest market, where CGM is used by an estimated 2.6% which is equivalent to 630,000 users. Each was identified diabetic in 2018, showing yearly growth of 117%. The world addressable market for CGM is predicted to be at 82B dollars per annum.
PennyStocks.News LLC was established to research a wide range of companies listed on the NYSE, NASDAQ, AMEX, OTCBB and Pink Sheets. We bring to you only the best penny stock news and trending stocks through our blogs, Social Media and E-mail newsletter.
The content of this article (hosted under the “www.pennystocks.news” domain) is for general information purposes only and does not constitute advice to buy or sell any particular stock or securities. PennyStocks.News, LLC. Tries to provide content that is true and accurate as of the date of writing; however, we give no assurance or warranty regarding the accuracy, timeliness, or applicability of any of the contents. Readers should always consult and seek the advice of an appropriately qualified professional before undertaking any transaction that involves the purchasing or selling of any stock or securities. PennyStocks.News, LLC. Accepts no responsibility for and excludes all liability in connection with browsing this Web site, use of information or downloading any materials from it, including but not limited to any liability for errors, inaccuracies, omissions, or misleading or defamatory statements.